ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1983 • ACR Convergence 2023

    Heated Mittens for Patients with Hand Osteoarthritis: A Randomized Trial

    Cecilie Bartholdy1, Anna Døssing2, Zara Stisen1, Sabrina Mai Nielsen3, Henning Bliddal1, Robin Christensen4, Marius Henriksen1 and Karen Ellegaard1, 1The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark, 2The Parker Institutte, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark, 3The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, 4Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark

    Background/Purpose: Hand Osteoarthritis (OA) is common and causes pain and disability. Heat is anecdotally known to moderate symptoms and is conditionally recommended as a treatment…
  • Abstract Number: 1984 • ACR Convergence 2023

    Therapeutic Effects of Pentosan Polysulfate Sodium on Clinical and Disease Modifying Outcomes in Subjects with Knee Osteoarthritis

    Mukesh Ahuja1, Donna Skerrett2, Curtis Gravance3, Divya Navuru4, Ravi Krishnan5, Charles Inderjeeth6, Philip Bloom7 and Schnitzer Thomas8, 1Paradigm Biopharmaceuticals, Oak Brook, IL, 2Paradigm Biopharmaceuticals, New York, NY, 3Paradigm Biopharmaceuticals, Melba, ID, 4Paradigm Biopharmaceuticals, Melbourne, Australia, 5Paradigm Biopharmaceuticals, Adelaide, Australia, 6University of Western Australia / Linear Clinical Research, Perth, Australia, 7Sportsmed Biologic, Melbourne, Australia, 8Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose: Osteoarthritis (OA) is an inflammatory joint disease, causing chronic pain, disability, and reduced quality of life. Affected joints may include the knee, hip, and…
  • Abstract Number: 1987 • ACR Convergence 2023

    Clinical and Imaging Characteristics of Individuals Who Underwent Knee Replacement During Years 3 to 5 in the FORWARD Study: A Post Hoc Analysis

    Philip Conaghan1, Felix Eckstein2, Wolfgang Wirth3, Marc Hochberg4, Ali Guermazi5, Luping Zhao6 and Niti Goel7, 1University of Leeds, Leeds, United Kingdom, 2Paracelsus Medical University, Institute of Anatomy & Ludwig Boltzmann Institute, and Chondrometrics GmbH, Salzburg, Austria, 3Paracelsus Medical University, Institute of Anatomy & Ludwig Boltzmann Institute, and Chondrometrics GmbH, Freilassing, Germany, 4University of Maryland School of Medicine, Baltimore, MD, 5Boston University, Boston, MA, 6TrialSpark, New York, NY, 7TrialSpark, Duke University, Durham, NC

    Background/Purpose: Sprifermin is an investigational intra-articular (IA) recombinant human truncated fibroblast growth factor-18 (rhFGF-18) therapy evaluated to date in three knee osteoarthritis (KOA) trials (NCT00911469…
  • Abstract Number: 1759 • ACR Convergence 2023

    Runx1 Is a Key Transcription Factor That Drives Synovial Fibroblast Pathogenicity in Rheumatoid Arthritis

    Christopher Mahony1, Samuel Kemble2, Paulynn Chin1, Cesar Prada3, Annie Hackland1, Patricia Reis-Nisa1, Lucy-Jayne Marsh1, Peter Keane1, Constanze Bonifer1, Christopher Buckley4, Stevephen Sansom5, Mark Coles4 and Adam Croft1, 1University of Birmingham, Birmingham, United Kingdom, 2University Birmingham, Rugeley, United Kingdom, 3The Kennedy Institute, Oxford, United Kingdom, 4University of Oxford, Oxford, United Kingdom, 5Kennedy Institute of Rheumatology, Oxford, United Kingdom

    Background/Purpose: Fibroblasts are key effector cells in rheumatoid arthritis (RA) underpinning joint inflammation and damage. Synovial tissue fibroblasts are heterogenous and acquire pathogenic cell states…
  • Abstract Number: 1752 • ACR Convergence 2023

    Fibroblast Expression of Neurotransmitter Receptor HTR2A Associates with Inflammation in Rheumatoid Arthritis Joint

    Chunyan Xiang1, Soomin Hong1, Bingjiao Zhao2, Hui Pi3, Fang Du4, Xingyu Lu5, Yuanjia Tang1, Nan Shen6, Chunxi Yang7 and Runci Wang8, 1Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, 2Department of Orthodontics, Shanghai Stomatological Hospital & School of Stomatology, Fudan University, Shanghai, China, 3Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China, 4Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, 5Department of Endocrinology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 6Shanghai Jiao Tong University School of Medicine, Shanghai, China, 7Department of Orthopedics, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, 8Renji hospital, Shanghai Jiaotong University, Pudong Xinqu, China

    Background/Purpose: Peripheral neuroimmune crosstalk plays a crucial role in the inflammatory process and bone metabolism in joint. Serotonin receptor HTR2A was reported to be expressed…
  • Abstract Number: 1985 • ACR Convergence 2023

    Preliminary Results for the Total Knee Replacement Coaching Program for Patients Preparing to Undergo Total Knee Arthroplasty, a Pilot Randomized Trial

    Noelia Hernandez1, Yuliana Dominguez Paez2, Assem Jabri2, Mackenzie Brown2, Geyanne Lui3, Wai-Kwong Hui4, Michael Parks4, Alejandro Gonzalez Della Valle4, Fred Cushner4, Peter Sculco4, Thomas Sculco4, Mathias Bostrom4, Alejandro Leali4, Jason Blevins4, Jose Rodriguez4, Gwo-Chin Lee4, Lisa Mandl5, Susan Goodman4, Samprit Banerjee2, Monika Safford6 and Iris Navarro-Millán7, 1Weill Cornell Medicine, The Bronx, NY, 2Weill Cornell Medicine, New York, NY, 3New York Institute of Technology, New York, NY, 4Hospital for Special Surgery, New York, NY, 5Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 6WCM Department of Medicine, New York, NY, 7Weill Cornell Medicine, Hospital for Special Surgery, New York, NY

    Background/Purpose: Up to 30% of patients with primary knee osteoarthritis (KOA) who have undergone Total Knee Replacement (TKR) continue to experience knee pain after surgery.High…
  • Abstract Number: 1762 • ACR Convergence 2023

    Single-cell RNA Sequencing Analysis and Immune Profiling of Antigen-specific T Cells in Patients with Rheumatoid Arthritis and Healthy Controls

    JING SONG1, Cliff Rims1, Matthew Dufort1, Peter Linsley1, Eddie James2 and Jane Buckner2, 1Benaroya Research Institute, Seattle, WA, 2Benaroya Research Institute at Virginia Mason, Seattle, WA

    Background/Purpose: Single-cell analysis has emerged as a powerful tool for investigating the transcriptomics and T-cell receptor (TCR) diversity in patients with rheumatoid arthritis (RA). However,…
  • Abstract Number: 1743 • ACR Convergence 2023

    Individuals At-risk for and with Rheumatoid Arthritis Have Elevated Fecal Concentrations of Arthritogenic Subdoligranulum didolesgii Correlating with CCP3 Antibodies

    Lyndsey Cole1, Sucai Liu2, Brendan Allen2, Marie Feser3, Kristen Demoruelle3, kevin Deane3, Michael Holer3 and kristine Kuhn2, 1University of Colorado School of Medicine, Centennial, CO, 2University of Colorado School of Medicine, Aurora, CO, 3University of Colorado Anschutz Medical Campus, Aurora, CO

    Background/Purpose: Our prior investigation identified a specific strain of Subdoligranulum didolesgii, S. dido7, to which dual IgA/IgG family plasmablast-derived monoclonal autoantibodies from individuals at-risk for…
  • Abstract Number: 1654 • ACR Convergence 2023

    A Peer Health Coached Resilience-Based Energy Management Program Was Effective in Improving Fatigue and Other Outcomes in People with Systemic Sclerosis: Results of a Randomized Controlled Trial

    Susan Murphy1, Yen Chen2, Mary Alore2, Sheri Hicks2, Adam Pape2, Afton Hassett2, Anna Kratz2, Daniel Whibley2, Alexandra Harper3, Suiyuan Huang2, Gina Jay2, Shannen Bolde2 and Dinesh Khanna2, 1University of Michigan, Plymouth, MI, 2University of Michigan, Ann Arbor, MI, 3University of Michigan, Ypsilanti Charter Twp, MI

    Background/Purpose: Systemic sclerosis (SSc), a rare autoimmune condition, has a high chronic symptom burden that can have dramatic, life-altering effects on function and quality of…
  • Abstract Number: 1763 • ACR Convergence 2023

    Asthma Severity Is Associated Increased Serum Anti-cyclic Antibody Level at Baseline and in Increase During Longitudinal Follow-up

    Drayton Rorah1, Linh Ngo2, Mario Castro2, Kristen Demoruelle3 and Scott Matson4, 1University of Kansas Medical Center, Kansas City, KS, 2University of Kansas School of Medicine, Kansas City, KS, 3University of Colorado Anschutz Medical Campus, Aurora, CO, 4University of Kansas School of Medicine, Kansas City, MO

    Background/Purpose: The lung airways have been implicated in the pathogenesis of RA. RA-associated autoantibodies, including anti-cyclic citrullinated peptide (anti-CCP) antibodies are found to be generated…
  • Abstract Number: 1663 • ACR Convergence 2023

    Clinically Severe Systemic Sclerosis Skin Harbors Inflammatory Fibroblasts Associated with Lymphocytes and Plasmacytoid Dendritic Cells

    Kimberly Lakin1, Robert Spiera2, Yaxia Zhang1, David Oliver1, Aliza Bloostein1, Hiranmayi Ravichandran3, Niroshana Anandasabapathy3, Franck Barrat1, Jessica Gordon1 and Dana Orange4, 1Hospital for Special Surgery, New York, NY, 2Hosptial for Special Surgery, New York, NY, 3Weill Cornell Medical College, New York, NY, 4The Rockefeller University, New York, NY

    Background/Purpose: We have previously shown that skin fibroblast activation is related to clinical severity and resolves with improvement in diffuse systemic sclerosis (dcSSc). The immune…
  • Abstract Number: 1042 • ACR Convergence 2023

    B-line of Lung Ultrasound Reflects Different Morphological Features on Chest HRCT Between Interstitial Lung Disease Associated with Systemic Sclerosis and Myositis

    Shinji Watanabe1, Keina Yomono2, Shintaro Yamamoto1, Mikito Suzuki3, Takahisa Gono4 and Masataka Kuwana4, 1Nippon Medical School, Tokyo, Japan, 2Nippon Medical School University, Tokyo, Japan, 3Nippon Medical School Hospital, Tokyo, Japan, 4Nippon Medical School Graduate School of Medicine, Tokyo, Japan

    Background/Purpose: Lung ultrasound (LUS) is a non-invasive imaging tool to evaluate distribution and severity of interstitial lung disease (ILD). Utility of LUS has been examined…
  • Abstract Number: 1462 • ACR Convergence 2023

    Cardiovascular Damage in Systemic Lupus Erythematosus Occurs at Early Stages of the Disease. Chronological Analysis of Damage Accrual in a Large Cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)

    Sara garcia Perez1, Jose-Maria Pego-Reigosa2, Irene Altabás González1, Norman Jiménez3, Victor Del campo Perez4, JULIA MARTINEZ BARRIO5, Maria Galindo-Izquierdo6, Jaime Calvo- Alén7, Esther Uriarte Isacelaya8, Eva Tomero Muriel9, Mercedes Freire González10, Victor Martinez-Taboada11, Paloma Vela12, Antonio Fernandez-Nebro13, Alejandro Olivé-Marqués14, Javier Narvaez15, Raúl Menor-Almagro16, Gregorio Santos Soler17, José Ángel Hernández Beriain18, Javier Manero ruiz19, Elena Aurrecoechea Aguinaga20, Oihane Ibarguengoitia-Barrena21, Carlos Montilla-Morales22, Gema Bonilla23, Vicente Torrente-Segarra24, Ana Paula Cacheda25, Maria J. García-Villanueva26, Clara Moriano Morales27, Concepción Fito Manteca28, Cristina Bohórquez29, Nuria Lozano Rivas30 and Iñigo Rúa-Figueroa31, 1Department of Rheumatology, University Hospital of Vigo. IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Vigo, Spain, 2Rheumatology, Hospital do Meixoeiro, Vigo, Spain, 3IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, 4Department of Epidemiology, University Hospital of Vigo, IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Vigo, Spain, 5Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, 6Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, 7Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, 8Rheumatology, University Hospital of Donosti, San Sebastián, Spain, 9Rheumatology, Hospital La Princesa, Madrid, Spain, 10Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, 11Rheumatology, Hospital Marqués de Valdecilla, Santander, Spain, 12Department of Rheumatology, University Hospital of Alicante, Alicante, Spain, 13Hospital Regional Universitario de Málaga, Malaga, Spain, 14Department of Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, 15Hospital Universitario de Bellvitge, Barcelona, Spain, 16Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, 17Rheumatology, Hospital Marina Baixa Villajoyosa, Alicante, Spain, 18Rheumatology, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, 19Department of Rheumatology, Hospital Universitario Miguel Servet, Zaragoza, Spain, 20Department of Rheumatology, Hospital Sierrallana, Torrelavega, Spain, 21Galdakao-Usansolo University Hospital, Bilbao, Spain, 22Rheumatology, University Hospital of Salamanca, Salamanca, Spain, 23Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, 24Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, 25Department of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain, 26Hospital Ramón y Cajal, Madrid, Spain, 27Rheumatology, Hospital Universitario de León, León, Spain, 28Department of Rheumatology, University Hospital of Navarra, Pamplona, Spain, 29Department of Rheumatology, University Hospital Príncipe de Asturias, Alcalá de Henares, Spain, 30Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, 31Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain

    Background/Purpose: Systemic Lupus Erythematosus (SLE) survival has improved during recent decades, so other outcomes like damage accrual become more relevant. Damage represents that clinical feature…
  • Abstract Number: 1474 • ACR Convergence 2023

    Associations and Outcomes of Critical Peripheral Ischemia in Systemic Lupus Erythematosus (SLE): Data from Indian SLE Inception Cohort for Research (INSPIRE)

    Vineeta Shobha1, Liza Rajasekhar2, Sandra Manuel3, Nayana V3, Ranjan Gupta4, Bidyut Das5, Parasar Ghosh6, Chengappa Kavadichanda7, Ashish J Mathew8, Manish Rathi9, Avinash Jain10, Sumithra Selvam3 and Amita Aggarwal11, 1St. John's National Academy of Health Science, Bangalore, India, 2Nizam's Institute of Medical Sciences, Madhapur, India, 3St. John's Research Institute, Bangalore, India, 4All India Institute of Medical Sciences, New Delhi, India, 5SCB medical college, Cuttack, India, 6Govt of West Bengal, Kolkata, India, 7Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, 8Christian Medical College, Vellore, India, 9Postgraduate Institute of Medical education and Research, Chandigarh, India, 10SMS Medical College, Lucknow, India, 11Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India

    Background/Purpose: Among the cutaneous manifestations of SLE, critical peripheral ischemia (CPI) including digital infarcts and gangrene are considered rare, gangrene occurring only in about 0.2%…
  • Abstract Number: 1052 • ACR Convergence 2023

    Unique Cellular and Autoantibody Signatures in Patients with irAEs Revealed by Longitudinal Immune Tracking

    Sokratis Apostolidis1, Kyra Sacksith1, Bria Fulmer1, Zoe Quandt2, Mark Anderson2, Terri Laufer3 and E. John Wherry1, 1University of Pennsylvania, Philadelphia, PA, 2University of California San Francisco, San Franscisco, CA, 3University of Pennsylvania, Philadlephia, PA

    Background/Purpose: The use of anti-PD-1 (aPD-1) immunotherapy has seen significant success in clinical practice, corresponding with a continued rise in clinical indications for multiple cancer…
  • « Previous Page
  • 1
  • …
  • 426
  • 427
  • 428
  • 429
  • 430
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology